Breaking News Instant updates and real-time market news.

RTRX

Retrophin

$20.08

-1.31 (-6.12%)

14:40
11/20/16
11/20
14:40
11/20/16
14:40

Retrophin reports additional Phase 2 data on sparsentan in glomerulosclerosis

Retrophin announced additional results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis, a rare kidney disorder. The new findings are being presented at the American Society of Nephrology Kidney Week. As announced in September, top-line data from DUET showed the sparsentan treatment group achieved statistical significance in the study's primary efficacy endpoint, reduction of proteinuria. An analysis of the secondary endpoint presented Saturday showed that a "significantly greater" proportion of patients receiving sparsentan achieved modified partial remission of proteinuria versus irbesartan patients. In addition, four patients receiving sparsentan achieved complete remission as compared to zero irbesartan patients. Also presented Saturday was a post-hoc, intention-to-treat analysis showing that the sparsentan treatment group again demonstrated a greater than two-fold reduction of proteinuria versus irbesartan. Further analysis of the safety database from the initial eight-week, double-blind treatment period also showed sparsentan was generally safe and well-tolerated. Detailed results of the above-mentioned findings include: "An analysis of the secondary endpoint, which showed that after the eight-week, double-blind treatment period, 28.1% of patients receiving sparsentan achieved modified partial remission of proteinuria, compared to 9.4% of irbesartan-treated patients. The proportion of patients achieving modified partial remission increased during the open label period. After 48 weeks of treatment with sparsentan, 57.7% of patients achieved modified partial remission. In addition, 50% of patients that transferred from irbesartan to sparsentan at the beginning of the open label period achieved modified partial remission after 40 weeks of treatment. Complete remission, defined as proteinuria less than 0.3 g/g, was achieved by four patients receiving sparsentan during the eight-week, double-blind treatment period, compared to zero irbesartan-treated patients. A post-hoc ITT analysis showed a statistically significant difference in the mean reduction of proteinuria from baseline for the sparsentan treatment group compared to the irbesartan group after the study's eight-week, double-blind treatment period. The sparsentan group achieved a 42.7% mean reduction of proteinuria compared to 15.7% for the irbesartan group. The ITT analysis also showed that after eight weeks of treatment with 400 mg and 800 mg of sparsentan, the mean reduction of proteinuria from baseline was 44.8%, compared to 15.9% for the irbesartan-treated patients in these two cohorts. During the eight-week, double-blind period, the incidence of treatment-emergent adverse events for the sparsentan group was similar to the irbesartan group, except for edema. The severity of edema did not significantly worsen from baseline and no patients withdrew from the study as a result of edema during the eight-week, double-blind treatment period... The incidence of serious adverse events was similar across both groups. Eighty-four percent of patients who completed the eight-week, double-blind treatment period continue to receive sparsentan in the open-label extension."

RTRX Retrophin
$20.08

-1.31 (-6.12%)

09/07/16
ROTH
09/07/16
NO CHANGE
Target $151
ROTH
Buy
Ligand target raised to $151 after sparsentan data at Roth Capital
Roth Capital analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $151 from $149 after the company's partner Retrophin (RTRX) announced positive data from the sparsentan Phase II study in focal segmental glomerulosclerosis patients. The analyst believes the data support a potential accelerated path forward and he reminds investors that FSGS has no approved therapies. Pantginis calls the data an important win for Ligand and Retrophin. He keeps a Buy rating on Ligand. The stock is up 7% to $115.21 in early trading.
09/07/16
LEER
09/07/16
NO CHANGE
LEER
Outperform
Retrophin price target raised to $32 from $27 at Leerink
Leerink analyst Joseph Schwartz said he is "very optimistic" that sparsentan will be approved after Retrophin announced top-line results for its Phase 2b DUET study. However, he thinks it is still unclear if the results reported today will be enough to support accelerated approval or if another clinical trial will be required. Schwartz raised his price target on Retrophin to $32 from $27 following the data release and keeps an Outperform rating on the shares.
09/08/16
BMOC
09/08/16
NO CHANGE
BMOC
Retrophin price target raised to $40 from $28 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Retrophin after the company reported Phase II data for its Sparsentan drug that the analyst views positively. Kim now sees a 45% chance of success for the drug, up from 25% previously. The analyst keeps an Outperform rating on the shares.
11/11/16
LEER
11/11/16
NO CHANGE
LEER
Outperform
Retrophin agreement for RE-024 bodes well for approval in 2019, says Leerink
Leerink analyst Joseph Schwartz says that the trial design for Retrophin's pending Phase 3 trial of RE-024 and the announced agreement with the FDA under the Special Protocol Assessment process for this trial bode well for potential approval in 2019. The analyst believes the company plans to initiate this trial by the end of 2016, with a drug that has shown "great promise" for the treatment of pantothenate kinase-associated neurodegeneration. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

NFLX

Netflix

$157.50

-0.52 (-0.33%)

13:27
06/27/17
06/27
13:27
06/27/17
13:27
Technical Analysis
Technical View: Netflix trades near session lows »

The stock is down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

VRX

Valeant

$17.11

0.03 (0.18%)

13:25
06/27/17
06/27
13:25
06/27/17
13:25
Recommendations
Valeant analyst commentary  »

Valeant debt-for-equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

AGNC

AGNC Investment

$22.28

0.07 (0.32%)

13:25
06/27/17
06/27
13:25
06/27/17
13:25
Options
AGNC Investment Corp. call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

13:20
06/27/17
06/27
13:20
06/27/17
13:20
General news
Treasury Action: yields extended their surge »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

13:17
06/27/17
06/27
13:17
06/27/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
06/27/17
06/27
13:16
06/27/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$24.27

0.25 (1.04%)

, XLK

Technology Select Sector SPDR

$55.52

-0.48 (-0.86%)

13:15
06/27/17
06/27
13:15
06/27/17
13:15
Technical Analysis
Technical View: S&P 500 mid-session chart update »

The S&P 500 (SPX) did…

XLF

Financial Select Sector

$24.27

0.25 (1.04%)

XLK

Technology Select Sector SPDR

$55.52

-0.48 (-0.86%)

SPY

SPDR S&P 500 ETF Trust

$242.76

-0.53 (-0.22%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.59

-1.48 (-0.95%)

13:08
06/27/17
06/27
13:08
06/27/17
13:08
Hot Stocks
Facebook reaches two billion users, Zuckerberg says »

Facebook CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

AVAV

AeroVironment

$30.97

0.2 (0.65%)

13:07
06/27/17
06/27
13:07
06/27/17
13:07
Conference/Events
AeroVironment management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 03

    Jul

  • 04

    Jul

  • 05

    Jul

CBI

CB&I

$19.00

4.6 (31.94%)

13:05
06/27/17
06/27
13:05
06/27/17
13:05
Options
CB&I call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$109.93

-0.12 (-0.11%)

13:05
06/27/17
06/27
13:05
06/27/17
13:05
Hot Stocks
Quest Diagnostics announces intent to acquire CCHC outreach lab business »

Quest Diagnostics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

FOX

21st Century Fox

$27.62

0.69 (2.56%)

, FOXA

21st Century Fox

$28.04

0.85 (3.13%)

12:57
06/27/17
06/27
12:57
06/27/17
12:57
Hot Stocks
FOX Sports partners with Facebook to stream Champions League soccer »

Twenty-First Century…

FOX

21st Century Fox

$27.62

0.69 (2.56%)

FOXA

21st Century Fox

$28.04

0.85 (3.13%)

FB

Facebook

$153.59

-1.48 (-0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

DHXM

DHX Media

$4.15

-0.0367 (-0.88%)

12:56
06/27/17
06/27
12:56
06/27/17
12:56
Conference/Events
DHX Media management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

IVZ

Invesco

$35.01

-0.005 (-0.01%)

12:55
06/27/17
06/27
12:55
06/27/17
12:55
Conference/Events
Invesco management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

FDX

FedEx

$215.36

-0.0025 (-0.00%)

12:52
06/27/17
06/27
12:52
06/27/17
12:52
Periodicals
TNT Express says hit with 'interference' with some of its systems, ABC News says »

A spokesman for TNT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jul

FDX

FedEx

12:50
06/27/17
06/27
12:50
06/27/17
12:50
Periodicals
FedEx 'operating normally' after functionality issues, Reuters reports »

A spokeswoman for FedEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jul

THC

Tenet

$19.43

0.6587 (3.51%)

12:50
06/27/17
06/27
12:50
06/27/17
12:50
Options
3K Tenet Healthcare Jul 20 calls trade for 88c »

3K Tenet Healthcare Jul…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

AMZN

Amazon.com

$993.98

-9.76 (-0.97%)

, WFM

Whole Foods

$42.69

-0.255 (-0.59%)

12:48
06/27/17
06/27
12:48
06/27/17
12:48
Hot Stocks
Kroger CEO: Whole Foods 'great fit' for Amazon »

Speaking in a CNBC…

AMZN

Amazon.com

$993.98

-9.76 (-0.97%)

WFM

Whole Foods

$42.69

-0.255 (-0.59%)

KR

Kroger

$22.97

0.355 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

SMSMY

Sims Metal

$10.30

-0.03 (-0.29%)

12:47
06/27/17
06/27
12:47
06/27/17
12:47
Upgrade
Sims Metal rating change  »

Sims Metal upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
06/27/17
06/27
12:45
06/27/17
12:45
General news
Breaking General news story  »

Federal Reserve Chair…

12:45
06/27/17
06/27
12:45
06/27/17
12:45
Conference/Events
Federal Reserve Board Chair Yellen speaks on global economic issues »

Federal Reserve Board…

DD

DuPont

$80.85

-0.31 (-0.38%)

, DOW

Dow Chemical

$63.30

-0.27 (-0.42%)

12:43
06/27/17
06/27
12:43
06/27/17
12:43
Periodicals
Mexico's Cofece grants conditional approval of DuPont-Dow tie-up, Reuters says »

Mexico's Federal…

DD

DuPont

$80.85

-0.31 (-0.38%)

DOW

Dow Chemical

$63.30

-0.27 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

TGT

Target

$52.22

0.74 (1.44%)

, AMZN

Amazon.com

$993.98

-9.76 (-0.97%)

12:41
06/27/17
06/27
12:41
06/27/17
12:41
Periodicals
Target prices next-day delivery service test $1 below Amazon's, StarTribune says »

Target (TGT), which just…

TGT

Target

$52.22

0.74 (1.44%)

AMZN

Amazon.com

$993.98

-9.76 (-0.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

CBI

CB&I

$19.08

4.68 (32.50%)

12:34
06/27/17
06/27
12:34
06/27/17
12:34
Hot Stocks
CB&I says court vindicates position in lawsuit against Westinghouse »

CB&I issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:30
06/27/17
06/27
12:30
06/27/17
12:30
General news
Treasury 5-year auction outlook: the auction should go well »

Treasury 5-year auction…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.